–Posiphen Restores Memory and Learning and Brain Function as well as Gut Motility and Coordination in Mice Models of AD and PD–
Berwyn, Pa., March 16, 2017 — QR Pharma, Inc., a privately held phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s (AD), Parkinson’s (PD) and other neurodegenerative diseases, today announced the presentation at the 13th AD/PD International Conference in Vienna, Austria, “Treating Acute and Chronic Neurodegeneration by Inhibiting Neurotoxic Aggregating Proteins” showing data relating to its lead clinical product candidate, Posiphen. The talk is scheduled for Sunday April 2, 2017 at 13:00.
The presentation highlights studies conducted by investigators from Columbia University characterizing the effects of Posiphen in a transgenic model of AD and from UCSF showing the effects of Posiphen in a transgenic model of PD. Posiphen administered daily orally to transgenic APP/PS1 mice preserved spatial working memory and brain function; while administered daily intraperitoneally to transgenic alpha-synuclein mice it restored gut motility and coordination.
“These are impressive results for Posiphen” commented Ottavio Arancio, MD, PhD, Professor at Columbia University. “The mechanism of action of the compound leading to pleiotropic effects in multiple neurodegenerative conditions is quite novel and very interesting.”
“These studies provide further confirmation of the neuroprotective effects of Posiphen,” stated Maria Maccecchini, Ph.D., President and CEO of QR Pharma. “They add to a deep data set supporting the unique activity and potentially broad application of Posiphen in chronic as well as acute neurodegenerative conditions.”
A full copy of the AD/PD talk entitled, “Treating Acute and Chronic Neurodegeneration by Inhibiting Neurotoxic Aggregating Proteins,” is available by visiting the “Scientific Presentations” in the Press Room section of QR Pharma’s website at www.qrpharma.com.
About QR Pharma, Inc.
Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.
QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com
Contact: Maria Maccecchini
Tel: 610-727 3710
Fax: 610 727 4001
Berwyn, PA, July 17, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that a report on the early stage clinical trials of its lead compound Posiphen® appeared online July 11, 2012 in the Journal of Neurology, Neurosurgery & Psychiatry and can be found online at: http://jnnp.bmj.com/content/early/2012/07/10/jnnp-2012-302589.full.
Posiphen has been shown in three early stage clinical studies to be safe and to significantly lower levels of amyloid beta, tau and inflammatory markers, which are the hallmarks of Alzheimer’s disease. The dosing, tolerability, and proof of mechanism studies were conducted by an international group of investigators testing Posiphen both in healthy volunteers and in patients with mild cognitive impairment (MCI), a condition that often progresses to Alzheimer’s. Posiphen works by inhibiting the production of neurotoxic proteins that derive from amyloid precursor protein (APP) and tau. This data provides key evidence to move the drug forward for further human testing.
QR’s lead compound, Posiphen®, is a small orally active compound with high blood brain barrier permeability. Posiphen reduces the levels of toxic proteins in the brains of patients with neurodegenerative disorders back to the levels found in normal healthy volunteers. By normalizing brain levels of alpha synuclein, beta amyloid and tau, it provides an avenue to treat Alzheimer’s and Parkinson’s disease early so as to prevent the onset or diminish the severity of cognitive decline. Since neurotoxic proteins cause inflammation in the brain, lowering their levels reduces inflammatory factors and lowers inflammation.
About QR Pharma, Inc.
Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders. QR currently has three product development programs – Posiphen for early stage Alzheimer’s and Parkinson’s disease, and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com.
Contact: Maria L. Maccecchini, CEO
Tel: 610 727 3710
WallStreet Journal – Serial Entrepreneur to Receive Award – November 1, 2011 Article >>>>>
MedCityNews – Serial Entrepreneur to Receive Award – October 31, 2011 Article >>>>>
Philadelphia Business Journal – QR Pharma wins ‘Best Early-Stage Company’ – October 1, 2010 Article >>>>>
September 21, 2010 QR Pharma, Inc. (QR), Radnor, PA: QR a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer’s disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen? and its metabolites in cell culture and in transgenic Alzheimer mice.
Posiphen® a small orally active compound, has been shown in cell cultures and in normal mice, AD transgenic mice and Down syndrome (DS) mice as well as in humans to reduce the synthesis of amyloid-β precursor protein (APP), which is cleaved into a number of toxic peptides. These peptides include N- and C-terminal fragments and amyloid-beta 42 (Aβ42) that is widely believed to be responsible for Alzheimer disease pathogenesis.
APP is cleaved into a number of toxic peptides, one of them being amyloid-β42 (Aβ42), the others being cleaved from the N- and C- terminal ends. These peptides attack multiple pathways of neuronal cell life leading to synaptic loss and nerve cell death. This induces dysfunction, neuroinflammation, and leads to cognitive impairment and neurodegeneration.
Posiphen® was found to be metabolized into three major metabolites. The primary activity is APP inhibition; it is exhibited by Posiphen® as well as all three metabolites. The other two activities, acetylcholinesterease inhibition and neuro-regeneration seem to be properties of one or another metabolite, but not of Posiphen. This grant will help evaluate the absolute and relative activities of Posiphen® and metabolites as well as test their activities in transgenic mice.
”APP mutations and duplications cause Familial Alzheimer’s disease. APP triplication causes Down syndrome and high levels of APP after head trauma, stroke and brain injury lead to neurodegeneration,” saidKumar Sambamurti, PhD, Professor of Neurosciences at MUSC. “Posiphen, an APP-lowering compound, should target all the toxic fragments cleaved from APP and therefore provide benefits beyond those realized by compounds that target Aβ”.
About QR Pharma, Inc.
Headquartered in Radnor, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, in diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Down Syndrome (DS). QR currently has two product development programs based on oral small-molecule, blood-brain barrier passable therapeutics that target two distinct pathways for the treatment of AD.www.qrpharma.com
About the Neurosciences Laboratory at MUSC:
The Sambamurti laboratory has a long-standing interest in understanding the biochemical basis of Alzheimer disease and its relationship to other neurodegenerative diseases. The laboratory has proposed a hypothesis that failure of membrane protein turnover (including APP) is the triggering event in Alzheimer disease pathogenesis. Thus, rather than viewing the amyloid peptide as a target for reduction, the lab focuses on facilitation of the turnover pathways for APP and other membrane proteins. Posiphen® constitutes a novel category of agents that aim to reduce the synthesis of APP, thereby reducing the load of this protein on its turnover pathways. The hypothesis extends to other degenerative diseases, including age-related macular degeneration and glaucoma. Dr. Sambamurti is also the Co-Director of the Carol Campbell brain bank.